UI Hospitals and Clinics

Clinical Trial Details

Short Title
Official Title
A Phase 2 Study of MLN8237 in Advanced / Metastatic Sarcoma

Participants in this research study have sarcoma that has spread or recurred.  The purpose of this research study is to find out what effects, good and/or bad, an experimental drug called MLN8237 has on participants and their sarcoma.

MLN8237 is a new investigational drug currently being tested for treatment of sarcoma. This study is approved and sponsored by the National Cancer Institute (NCI). An investigational drug is a medication that has not been approved for use by the U.S. Food and Drug Administration (FDA). The drug is only available in a clinical trial.

Approximately 15 people will take part in this study conducted by investigators at the University of Iowa.  Up to 135 subjects will take part in this study at serveral cancer centers nationwide. This includes up to about 30 subjects at Memorial Sloan-Kettering Cancer Center.

Start Date
January 10, 2013
End Date
January 10, 2023
Gender Preference
Age Group
18 - 99 years
Principal Investigator
Mohammed Milhem, MD
Contact Info

Janan Geick-Miller, 319-356-3944

ALLIANCE A091102 ; cancer ; IRB#201212726 ; milhem ; MLN8237 ; sarcoma ;

We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.